New gel aims to stop bleeding in kidney surgery – but study never started
NCT ID NCT07284953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a material called PuraBond that helps stop bleeding during robotic surgery for kidney cancer. The goal was to see if it works safely and helps the kidney heal. However, the study was withdrawn before any participants were enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Royal Wolverhampton NHS Trust
Wolverhampton, WV10 0QP, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?